About the Ypsomed Group
The Ypsomed Group is the leading developer and manufacturer of injection and infusion systems for self-medication and a renowned diabetes specialist with over 30 years’ experience. As a leader in innovation and technology, Ypsomed is the preferred partner for pharmaceutical and biotech companies for the supply of pens, autoinjectors and infusion systems to administer liquid drugs. Ypsomed promotes and sells its product portfolio under the umbrella brands mylife Diabetescare directly to patients or through pharmacies and clinics and under YDS Ypsomed Delivery Systems business-to-business to pharmaceutical companies. Ypsomed has its headquarters in Burgdorf, Switzerland, and operates a global network of manufacturing sites, subsidiaries and distributors. The Ypsomed Group employs almost 1500 employees.
Ypsomed Diabetes Care
With its mylife Diabetescare brand, Ypsomed operates successfully in the B2C business with products and services for people with diabetes mellitus. The product portfolio includes: insulin pumps, infusion sets, pen needles, blood glucose monitoring systems and other diabetes supplies. Products are distributed via Ypsomed’s subsidiaries to hospitals, doctors, pharmacies and patients, and via distributors (pen needles).
Diabetes: A global disease with pandemic growth predicted in the coming 20 years. Currently diabetes is growing at approximately 9% p. a. Due to that fact Ypsomed is expanding its network of subsidiaries consequently with its outstanding product portfolio.
Ypsomed Delivery Systems
Our pharmaceutical and biotech customers purchase injection systems and corresponding services under the YDS brand, Ypsomed Delivery Systems. They do this via the industry leader, as Ypsomed is the world’s largest developer and manufacturer of pens and autoinjectors with which patients can administer their liquid medication subcutaneously themselves.
Trends for future drugs: Drugs are becoming more speci-fic, e.g. in the treatment of autoimmune diseases. Insteadof a generic drug (e.g. Humira®), a large number of new,very specific drugs come onto the market. New drugs forAlzheimer's disease, obesity and rare diseases are being developed. Cancer drugs are also becoming more specific. Efforts to develop active ingredients for subcutaneousinjection open up opportunities for self-medication with auto- and patch injectors.
In the 2018/19 financial year, our sales will be in the same order of magnitude as in the financial year 2017/18. At the EBIT level, we expect a result of CHF 73 million for the current financial year.
Key financial figures: multi-year overview
|In thousand CHF||2017/18||2016/17||2015/16||2014/15|
|Sales of goods and services||466119||389 555||336 922||306 632|
|Gross Profit||139825||125 478||103 187||85 850|
|Operating Profit||61070||55 298||44 435||28 546|
|Net Profit||52060||46 247||35 812||19 395|
|EBITDA1||95539||87 763||73 270||57 369|
|Cash flow from operating activities||53269||75 064||76 687||41 381|
|Year-end headcount||1451||1 314||1 166||1 050|
1 Operating proﬁt before depreciation and Amortisation.